Work

Phase I evaluation of PRGN-2009 alone and in combination with bintrafusp alfa in patients (pts) with recurrent/metastatic (R/M) HPV-associated cancers (HPV-C).

Year: 2023

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2023.41.16_suppl.2628

Authors: Charalampos S. Floudas, Julius Strauss, Jason M. Redman, Danielle M. Pastor, Evrim B. Turkbey, Renee N. Donahue, Caroline Jochems, Sheri McMahon, Elizabeth Lamping, Lisa M. Cordes, Seth M. Steinberg, Jenn Marte, Douglas E Brough, Amy Lankford, Jeffrey Schlom, James L. Gulley

Institutions: National Institutes of Health, National Cancer Institute, Center for Cancer Research, National Institutes of Health Clinical Center

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: National Institutes of Health

OpenAlex ID: W4379282864

Cites:

Cited by: 11

Related to: 10